Toluene

Toluene

SCHEMBL451517

CC(C)(C)N.Cc1ccccc1

nearest known ligand 0.69

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACEIDH1

The experimentally established mechanism targets of Toluene. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
ACHE P22303 6/20 0.69
TSHR P16473 2/20 0.69
LMNA P02545 1/20 0.69
ALOX12 P18054 1/20 0.69
TAAR1 Q96RJ0 2/20 0.46
SLC6A2 P23975 1/20 0.46
KCNN4 O15554 1/20 0.43
HPGD P15428 1/20 0.42
TDP1 Q9NUW8 1/20 0.41
CYP2C19 P33261 1/20 0.40
KIF11 P52732 2/20 0.39
CES2 O00748 1/20 0.39
CES1 P23141 1/20 0.39
MAPK1 P28482 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Toluene SCHEMBL11296763 0.88 TSHR (0.61) ACHETSHRLMNAALOX12TAAR1
Toluene SCHEMBL2566607 0.83
Toluene SCHEMBL2508427 0.83
Toluene SCHEMBL10989418 0.83
Toluene SCHEMBL175861 0.83 ACHE (1.00) ACHETSHRLMNAALOX12HPGD
Toluene SCHEMBL4429042 0.83 ACHE (1.00) ACHETSHRLMNAALOX12HPGD
Toluene SCHEMBL1 0.83
SCHEMBL12344943 0.83 ACHE (1.00) ACHETSHRLMNAALOX12HPGD
Toluene SCHEMBL8824270 0.83 ACHE (1.00) ACHETSHRLMNAALOX12HPGD
Toluene SCHEMBL8938900 0.83 ACHE (1.00) ACHETSHRLMNAALOX12HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2142508-A2 PROCESS FOR THE PREPARATION OF SODIUM SALT OF L-(((L(R)-(3-(2-(7-CHLORO-2- QUINOLINYL)-ETHENYL)PHENYL)-3-(2-(L-HYDROXY-L- METHYLETHYL)PHENYL)PROPYL)SULFANYL)METHYL)CYCLOPROPANEACETIC ACID Zaklady Farmaceutyczne "Polpharma" S.A. (PL) 2010-01-13 EP claimed
WO-2008136693-A2 PROCESS FOR THE PREPARATION OF SODIUM SALT OF L-(((L(R)-(3-(2-(7-CHLORO-2- QUINOLINYL)-ETHENYL)PHENYL)-3-(2-(L-HYDROXY-L- METHYLETHYL)PHENYL)PROPYL)SULFANYL)METHYL)CYCLOPROPANEACETIC ACID ZAKLADY FARMACEUTYCZNE POLPHARMA SA (PL) 2008-11-13 WO claimed
US-20260117617-A1 EXPANDABLE POLYMER GROUT FOR SAND CONTROL IN A WELL CHEVRON USA INC (US) 2026-04-30 US disclosed
US-12612839-B1 Expandable polymer grout for sand control in a well CHEVRON U.S.A. INC. (US) 2026-04-28 US disclosed
EP-3898205-B1 SURFACE TREATMENT TO ENHANCE BONDING OF COMPOSITE MATERIALS CYTEC IND INC (US) 2026-03-11 EP disclosed
US-20260063011-A1 EXPANDABLE POLYMER GROUT FOR WELLBORE APPLICATIONS CHEVRON USA INC (US) 2026-03-05 US disclosed
US-12428931-B2 Cement top jobs in wellbore annuli using expandable compositions CHEVRON U.S.A. INC. (US) 2025-09-30 US disclosed
US-20250250878-A1 EXPANDABLE POLYMER GROUT FOR SEALING SUBTERRANEAN FORMATIONS CHEVRON U.S.A. INC. 2025-08-07 US disclosed
US-12378842-B1 Expandable polymer grout for sealing subterranean formations CHEVRON U.S.A. INC. (US) 2025-08-05 US disclosed
US-12134950-B2 Deployment methods for expandable polymer grout for plug and abandonment applications CHEVRON U.S.A. INC. (US) 2024-11-05 US disclosed
US-20240191594-A1 Cement Top Jobs In Wellbore Annuli Using Expandable Compositions CHEVRON U.S.A. INC. 2024-06-13 US disclosed
EP-2142508-A2 PROCESS FOR THE PREPARATION OF SODIUM SALT OF L-(((L(R)-(3-(2-(7-CHLORO-2- QUINOLINYL)-ETHENYL)PHENYL)-3-(2-(L-HYDROXY-L- METHYLETHYL)PHENYL)PROPYL)SULFANYL)METHYL)CYCLOPROPANEACETIC ACID Zaklady Farmaceutyczne "Polpharma" S.A. (PL) 2010-01-13 EP disclosed
WO-2009091909-A2 DEGRADABLE NON-AQUEOUS GEL SYSTEMS M-I L.L.C. (US) 2009-07-23 WO disclosed
WO-2008147641-A1 ISOCYANATE-EPOXY FORMULATIONS FOR IMPROVED CURE CONTROL DOW GLOBAL TECHNOLOGIES INC. (US) 2008-12-04 WO disclosed
WO-2008136693-A2 PROCESS FOR THE PREPARATION OF SODIUM SALT OF L-(((L(R)-(3-(2-(7-CHLORO-2- QUINOLINYL)-ETHENYL)PHENYL)-3-(2-(L-HYDROXY-L- METHYLETHYL)PHENYL)PROPYL)SULFANYL)METHYL)CYCLOPROPANEACETIC ACID ZAKLADY FARMACEUTYCZNE POLPHARMA SA (PL) 2008-11-13 WO disclosed
WO-2008134359-A1 USE OF ELASTOMERS TO PRODUCE GELS FOR TREATING A WELLBORE M-I LLC (US) 2008-11-06 WO disclosed
EP-1669385-A1 Continuous method for manufacturing an acid functional blocked solid isocyanate Bayer MaterialScience LLC (US) 2006-06-14 EP disclosed
US-20060122357-A1 Continuous method for manufacturing an acid functional blocked solid isocyanate BAYER MATERIALSCIENCE LLC 2006-06-08 US disclosed
US-6762322-B1 CYCLIZING IMINE GROUP TO OXAZIRIDINE RING USING PEROXYSULFATE OXIDIZING AGENT AND REARRANGING TO OXIME FUNCTIONALITY GOODYEAR TIRE & RUBBER COMPANY 2004-07-13 US disclosed
US-20040122225-A1 PREPARATION OF NITRONE DERIVATIVES THE GOODYEAR TIRE & RUBBER COMPANY 2004-06-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040122225-A1 PREPARATION OF NITRONE DERIVATIVES NOX5, NDUFS5, NDUFS8 ACHE 2586/4885TSHR 3431/4885LMNA 698/4885
US-20260063011-A1 EXPANDABLE POLYMER GROUT FOR WELLBORE APPLICATIONS HPSE, HIRIP3, WEE2 ACHE 2827/4885TSHR 4686/4885LMNA 3559/4885
US-12612839-B1 Expandable polymer grout for sand control in a well GET3, USE1, WEE2 ACHE 1815/4885TSHR 4839/4885LMNA 1332/4885
US-20260117617-A1 EXPANDABLE POLYMER GROUT FOR SAND CONTROL IN A WELL GET3, WEE1, WEE2 ACHE 1710/4885TSHR 4849/4885LMNA 1413/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.